Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

GPCR vs CELU: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

GPCR Captures Overall Composite Edge (40.9 SELL vs 42.9 HOLD), While CELU Leads 3–2 on Growth & Valuation Pillars

GPCR Overall Winner 6-Pillar Tally: GPCR 2 – 3 CELU (1 Tie) Matrix Metrics: GPCR 6 – 2 CELU

As of Nov 20, 2026, Structure Therapeutics Inc. (GPCR) captures the overall head-to-head institutional edge over Celularity Inc. (CELU) on higher Unified Composite conviction (40.9/100 SELL vs. 42.9/100 HOLD) after splitting the core matrix 6–2 (led by Growth & Scale, Profitability & Quality), while CELU wins 3–2 across the 6-pillar growth and valuation breakdown. GPCR trades at $16.13 (N/M Forward P/E, 0.0% operating margin) versus CELU at $0.46 (N/M Forward P/E, -254.0% operating margin).

  • Composite vs. Pillar Nuance: While CELU currently prints a higher short-term Unified Composite Score (42.9/100 HOLD vs. GPCR 40.9/100 SELL), GPCR captures the overall institutional head-to-head verdict (6–2 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -254.0% operating margin) and revenue trajectory (+0.0% vs. -5.3% YoY).
  • Technical & Structure Timing Caution: GPCR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.9); meanwhile CELU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About GPCR vs CELU
GPCR NASDAQ Head-to-Head Winner
Structure Therapeutics Inc. American Depositary Shares
Pharmaceutical Preparations
$16.13
-5.78% 1D
Market Cap $1.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.31β · 58% Vol
Unified Composite Score
40.9 / 100 SELL
Tech 25.0 Fund 43.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -30.4%), weak momentum, RSI 22
RSI-14: 21.9 · SMA20: $19.99 · SMA50: $25.49
CELU NASDAQ
Celularity Inc. Class A Common Stock
Pharmaceutical Preparations
$0.46
-1.05% 1D
Market Cap $15.2M
TTM Revenue $19M
Forward P/E N/M
Beta / 30D Vol 2.01β · 135% Vol
Unified Composite Score
42.9 / 100 HOLD
Tech 25.0 Fund 48.0 Flow 67.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.3%), weak momentum, RSI 27
RSI-14: 26.9 · SMA20: $0.71 · SMA50: $1.08

6-Pillar Scorecard Institutional Category Breakdown (GPCR 2 – 3 CELU)

Columns: Metric · GPCR · CELU
1. Valuation Multiples CELU
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 2.7x
2. Growth & Scale GPCR
Revenue Growth (YoY) +0.0% -5.3%
Earnings Growth (YoY) +0.0% -61.3%
TTM Revenue (USD) N/A $19M
Market Cap $1.2B $15.2M
3. Profitability & Quality GPCR
Gross Margin N/A 19.2%
Operating Margin 0.0% -254.0%
Net Profit Margin 0.0% -245.7%
Return on Equity (ROE) -29.5% -6367.2%
4. Balance Sheet & Cash Flow CELU
Cash Generation (TTM) N/A -$8.9M
Cash Flow Margin N/A -47.8%
Net Cash / Leverage $17.12 Book/Sh · -29.5% ROE $35M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CELU
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 120.4% (<1st %ile) 116.6% (50th %ile)
Put/Call OI Skew Thin ADR Chain 3.60x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: GPCR (6) vs CELU (2)
Institutional Metric GPCR CELU Criterion Row Edge
Market Capitalization
Scale
$1.2B $15.2M Larger Scale GPCR
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -5.3% Higher Growth GPCR
Operating Margin (TTM)
Profitability
0.0% -254.0% Higher Margin GPCR
Net Profit Margin
Profitability
0.0% -245.7% Higher Margin GPCR
Return on Equity (ROE)
Capital Efficiency
-29.5% -6367.2% Higher ROE GPCR
52-Week Range Position
Momentum
0% ($16–$95) 2% ($0–$3) Stronger Trend CELU
Beta / 30D Volatility
Risk Regime
1.31β · 58% Vol 2.01β · 135% Vol Lower Realized Risk GPCR
Unified Institutional Score
Composite Signal
40.9 / 100 (SELL) 42.9 / 100 (HOLD) Higher Composite CELU
Trailing 12M Revenue (USD)
Operating Scale
N/A $19M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 19.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 2.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($17.12 Book/Sh · -29.5% ROE) -$8.9M ($35M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon GPCR +29.45 pp
GPCR: -26.45% · CELU: -55.9%
3M Horizon CELU +26.85 pp
GPCR: -67.09% · CELU: -40.24%
6M Horizon CELU +12.05 pp
GPCR: -58.84% · CELU: -46.79%
1Y Horizon GPCR +16.78 pp
GPCR: -55.82% · CELU: -72.6%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GPCR vs CELU. Trailing 12-month operating profitability (GPCR 0.0% vs CELU -254.0%) and valuation multiples (GPCR N/M vs CELU N/M Forward P/E) are benchmarked directly in Pillar 4 below.

GPCR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-29.5% · N/M
CELU ADR TTM Benchmark FX-Normalized USD
TTM Revenue$19M
Gross Margin19.2%
Op. Margin-254.0%
ROE / Fwd P/E-6367.2% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
GPCR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 120.4%
IV Percentile <1st %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact GPCR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CELU BREAKDOWN
60d in phase · OBV NEUTRAL
Current IV 116.6%
IV Percentile 50th %ile
Put/Call OI Skew 3.60x (Put-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CELU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
GPCR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CELU Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.2M market capitalization and -254.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ GPCR vs CELU Key Questions & Quantitative Answers

As of Nov 20, 2026, Structure Therapeutics Inc. (GPCR) captures the overall head-to-head institutional edge over Celularity Inc. (CELU) on higher Unified Composite conviction (40.9/100 SELL vs. 42.9/100 HOLD) after splitting the core matrix 6–2 (led by Growth & Scale, Profitability & Quality), while CELU wins 3–2 across the 6-pillar growth and valuation breakdown. GPCR trades at $16.13 (N/M Forward P/E, 0.0% operating margin) versus CELU at $0.46 (N/M Forward P/E, -254.0% operating margin). Composite vs. Pillar Nuance: While CELU currently prints a higher short-term Unified Composite Score (42.9/100 HOLD vs. GPCR 40.9/100 SELL), GPCR captures the overall institutional head-to-head verdict (6–2 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -254.0% operating margin) and revenue trajectory (+0.0% vs. -5.3% YoY). Technical & Structure Timing Caution: GPCR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.9); meanwhile CELU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

GPCR leads the Growth & Scale pillar: GPCR posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CELU at -5.3% YoY revenue growth and -61.3% YoY earnings growth on $19M TTM revenue (19.2% gross margin, -254.0% operating margin). On trailing 12-month operating scale, GPCR generates N/A in USD-normalized revenue versus $19M for CELU. In operating R&D and SG&A reinvestment, GPCR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CELU.

CELU screens cheaper on headline valuation multiples. GPCR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CELU trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.7x EV/Revenue (-47.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GPCR (-29.5% ROE) versus CELU (-6367.2% ROE) capital efficiency.

In options market volatility and institutional positioning, GPCR carries 120.4% implied volatility (<1st %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.31β · 58% Vol realized risk). By comparison, CELU carries 116.6% implied volatility (50th %ile, Balanced (25th–60th %ile)), a 3.60x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.01β · 135% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.